Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
N/A
1(25.0%)
4Total
Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03153683Recruiting

Brain, Blood And Clot or Tissue Registry And Collaboration

Role: lead

NCT02912663Phase 1Completed

Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.

Role: lead

NCT02514902Not ApplicableCompleted

Stroke and Traumatic Acute Brain Injury Line Indicator System for Emergent Recognition (STABILISER-I)

Role: lead

NCT02235558Phase 1Completed

Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke

Role: lead

NCT02823106Phase 1Withdrawn

Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response

Role: lead

All 5 trials loaded